Merck KGaA Flags 2026 Earnings Drop as Mavenclad Faces Generics
Merck KGaA forecast a sluggish year ahead, with the possibility of falling profits, as generic competition for its multiple sclerosis drug Mavenclad weighs on its health care division.
By Sonja Wind · Bloomberg
Merck KGaA forecast a sluggish year ahead, with the possibility of falling profits, as generic competition for its multiple sclerosis drug Mavenclad weighs on its health care division.